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The Formulary Fix Buries Fritz &
Harvey: Drug Promotion Escapes its
Past Constraints
James T. O’Reilly*
I. Setting the Scene
The young in-house lawyer, a recent W&L Law graduate,
enters the meeting on the executive floor of corporate headquarters
and observes the vigorous debate among the team of
pharmaceutical marketing experts. One group wants to ask senior
management to invest $7 million to conduct an additional clinical
trial at three prestigious hospitals, in order to request that the
FDA would allow the company to make the newly expanded claim
that their ten-year-old acne drug “Alepsima” will cure hangnail.
This is the correct “by the book” route1 to selling a greater
volume of Alepsima, at a greater profit, beginning in an estimated
twenty-six months following submission of test results to the Food
and Drug Administration (FDA). They expect that a label change
will be approved, after the FDA allows the hangnail claim
following a detailed medical evaluation of the clinical trial results,
and after the FDA’s team of reviewers of the company’s
supplemental new drug application feel they have seen enough
supporting data, so that their approval of this drug for hangnail
will be unassailable.
Another expert group of company marketers wants to push
more Alepsima sales today, by overtly promoting its use against
hangnails in trade-show booth presentations and sales visits to
dermatologists and podiatrists, without awaiting FDA blessings.
This group cites an in-house dermatology research team that
conducted a less formal review of the technical literature, and
found sixteen doctors whose hangnail patients had responded well
* Professor, University of Cincinnati College of Medicine.
1. 21 C.F.R. § 314.70 (2016). The supplemental new drug application must
be accompanied by valid clinical data acceptable to FDA scientists.
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to their use of Alepsima. The first group replies, “No! Such
aggressive claims will get us into trouble.”
At the head of the table, the division Vice-President turns to
the young lawyer and says: “How much trouble will we be in, if we
use the hangnail claim in sales presentations to sell Alepsima to
doctors tomorrow?”
Hundreds of miles away, the maker of Hangtough® ointment
has its sales team wondering what defensive moves will be needed,
in response to rumors that Alepsima might intrude upon
Hangtough’s FDA-approved use as the best-selling brand for
hangnails. Is litigating the right strategy? Will the FDA respond
to our pleas, and defend us? How much is our lost market share
potentially worth?
And, a thousand miles away, the Regional Drug Compliance
Director of the FDA is oblivious to both, bemoaning yet another
budget cut from the Trump Administration, which reduces the
FDA’s ability to monitor claims on drug labels for the latest
gene-derived cancer drugs. If she had been asked she would
probably respond: “Hangnail? Who cares? When we have death
risks surrounding neonatal stem cell infusion, why spend the
scarce resources we have on these less impactful decisions?”
So, the conflicts of Lanham Act2 remedy, the long shot of FDA
and Justice Department cooperation to halt misbranding, and the
potential for jeopardizing an income stream of millions to win
marginal additional sales in the thousands, makes the young
lawyer hesitate. If she or he is as bright as Chris Hurley, there will
be a brilliant answer. Charles Dickens would see me as the Ghost
of Christmas Past, and Chris as the smiling angel of the
pharmaceutical industry’s future. What the Dickens should come
from this scenario today?

2. Trademark Act of 1946 (Lanham Act), Pub. L. No. 79-489, 60 Stat. 427
(codified as amended at 15 U.S.C. §§ 1051–1127 (2012)).
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II. Yesterday’s Blues
Fritz Lanham of Texas3 and Harvey Wiley of Indiana4 never
met, but their respective legacies in legislation have given the
federal courts numerous challenges to decipher. Fritz intended to
update the federal trademark laws in the boom years of postwar
commerce after World War II; the less busy federal courts had the
time and the intellectual power to help Fritz create the legal
protection of the statutory rights of trademark owners.
Harvey wanted to stop snake-oil salesmen who hawked their
claimed curative potions with loud promises but an absence of
supporting data and safety research.5 If Harvey and Fritz had met,
chances are they would not have regarded the complexities of the
2018-era presentation of drug benefit claims6 as a theme for new
legislative attention. Their federal judges had the time and the
docket capacity to make such intellectually fascinating decisions.
Our district court judges today are swamped; just ask them when
the vacant seats on their district court bench will be filled. So, a
little statutory ambiguity about the additional benefit claims for a
drug seems to be fine, since statutes tend to grow ambiguities as
they age.
Ambiguities in statutory coverage are as old as Hammurabi or
at least the Magna Carta. The king’s interpretation of the royal
charter controlled the outcome; the royal bench of jurists, like the
Royal Assizes of olden times, could offer their interpretation, but
the actual creator of that charter was always there to say what had
been intended. So, the American Article III judges, begotten by our
anti-royalist Constitution, should in theory enjoy the opportunity
to bring Harvey and Fritz together, as the Food Drug & Cosmetic
3. Rep. Fritz Lanham represented the 12th Congressional District in Texas
and sponsored the Lanham Act. Id. §§ 1051–1127.
4. State Chemist of Indiana, later Chief Chemist of the U.S. Department of
Agriculture, and first Commissioner of Food & Drugs after adoption of the Pure
Foods & Drugs Act. Federal Food and Drugs Act of 1906 (Wiley Act), Pub. L. No.
59-384, 34 Stat. 768 (repealed 1938).
5. A useful biography is found on Wikipedia. Harvey Washington Wiley,
WIKIPEDIA,
https://en.wikipedia.org/wiki/Harvey_Washington_Wiley
(last
updated Oct. 31, 2017) (last visited Jan. 19, 2018) (on file with the Washington
and Lee Law Review).
6. See 21st Century Cures Act, Pub. L. No. 114-255, § 3037, 130 Stat. 1033,
1105 (2016) (codified as amended at 21 U.S.C. § 355 (2012)).

666

75 WASH. & LEE L. REV. 663 (2018)

Act7 and the Lanham Act8 might be used to focus the legal
community’s attention upon sales of hangnail drugs or other
weightier problems.
And so, on this same day as the stage is set for our dermatology
drama, Mr. John Jones, suffering from painful hangnail, asks the
advanced practice nurse in the local retail store “Minute Clinic”
what she can give him for his annoying dermatological problem.
“On aisle three we have Hangtough, but take this prescription to
the counter and they’ll give you Alepsima, and it should be cured
more quickly!”
But first, we go back to visit our young lawyer in the drug
company conference room. The Vice President’s question still
hangs in the air: what trouble will we be in by promoting
Alepsima?
One of Virginia’s brightest young lawyers, after his W&L
graduation in a few months, will be answering that question
bravely in his excellent analysis of the interweaving of Lanham
and Food Drug & Cosmetic Act remedies. Yet this tired and
somewhat more experienced counselor with scars and battle stars
from many past battles over forty-four years, would hesitate and
will say: “It depends!”
III. Warfare in the Pharma Trenches
The commercial wars among pharmaceutical companies of
today are different than in ancient times. In the old days, drug
marketing lawyers would think “Lanham Act unfair competition”
was occurring if our sales representative had found a competitor’s
sales brochure making the unapproved new claims, typically inside
a dermatologist’s waiting room. Trade shows, contract reps, detail
reps and continuing medical education were the battlefields of old
time prescription drug sales.9 Nuances of the Lanham Act
resonated with courts and earned scholarly attention in esoteric
7. Federal Food, Drug, and Cosmetic Act, Pub. L. No. 75-717, 52 Stat. 1040
(1938) (codified as amended at 21 U.S.C. § 321 et seq. (2012)).
8. Trademark Act of 1946 (Lanham Act), Pub. L. No. 79-489, 60 Stat. 427
(codified as amended at 15 U.S.C. §§ 1051–1127 (2012)).
9. 2 JAMES T. O’REILLY & KATHARINE A. VAN TASSEL, FOOD & DRUG
ADMINISTRATION ch. 15 (4th ed. 2017).
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analyses. In the primary article of this issue, W&L’s Chris Hurley
has spotted those issues very well.
“Back in the day,” some tradition-bound drug companies
fought the last war, not the new war, and that has made all of the
difference. When the Supreme Court in Weinberger v. Hynson,
Westcott & Dunning, Inc.10 allowed great deference to an FDA
administrative remedy, withdrawal of the New Drug Application
(NDA) as punishment for misconduct, the message sent by the
FDA and the Court was echoed in company meetings with the FDA
for years: beware losing your base product approval. If you dare to
push the envelope of permissible claims, then the FDA would win
in court, after Hynson, when the FDA undertakes the withdrawal
of your prior FDA approval of your drug.
Any old-school commentator is in danger of talking “inside
baseball” as these nuances evolve, but their relevance will be
apparent in retrospective. The Hurley Note’s analysis is very well
stated. But, the FDA’s major years of achieving practical success
with threats, came without the FDA having to bring much
litigation to police the marketers’ efforts for expansion of product
benefit claims. In poker terms, the FDA could just call for “Hynson
deference,” and the drug industry player would fold its cards, the
benefit would not be claimed, and no court would need to become
involved.11
Warriors for the totally compliant drug maker in the olden
days might beg the FDA to act against the aggressive hustling of
an unapproved claim for a competing drug. But, the agency would
choose its targets very strategically, in order to scare many other
firms into compliance with one visible victim. The FDA could use
misbranding or an “unapproved new drug” violation as the
charge,12 and would have a variety of ways to attack. On rare
occasions, there would be a competing drug firm, behind the
scenes, begging the FDA to initiate a blockbuster criminal
prosecution that, when given publicity, would drive the stock price
of the offending drug firm into the ditch. The drug promotion
10. 412 U.S. 609 (1973).
11. See generally James T. O’Reilly, Losing Deference in the FDA’s Second
Century: Judicial Review, Politics, and a Diminished Legacy of Expertise, 93
CORNELL L. REV. 939, 944 (2008).
12. 21 U.S.C. §§ 321, 333, 355 (2012).
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conflict’s harsh bite was being threatened at a time when
promotion of new uses for an approved drug was all about sales
and the stock price of the pharmaceutical marketer.
I plead guilty to having been a master practitioner of those
black arts of stimulating enforcers to act against bad behavior. For
reasons of legal ethics, I cannot reveal whose inbox received a
letter bomb and who did a nationwide recall while paying a very
large penalty. But, it felt terrific when a month later there came
an unsolicited call from a headhunter legal search firm who
described a regulatory law job in the home city of my wounded
competitor. (I declined to interview after telling the recruiter “I
made that opening, I’m not going to fill it!”)
That old-style war of off-label promotion is not yet over. On
September 22, 2017, we heard the last of a long-running tragedy,
the Novelion case.13 Novelion bought a tech company and inherited
a hugely expensive cancer drug that had been approved only for
certain rare cancer cases, one medical use that costs private payers
or Medicare between $250,000 and $300,000 per rare cancer
patient per year. I say “inherited” because the earlier drug firm
that launched the drug, Aegerion, imploded. Its sales reps had
been hustling the very expensive drug for as-yet-unapproved
additional types of cancer. Their hustle to sell more to Medicare
and Medicaid patients crossed the line, and three employees hired
an attorney and filed a False Claims Act complaint (probably after
being terminated).14
The outcome of the Novelion case was perhaps the last battle
using the old ways of war: criminal convictions for two counts of
misbranding the drug; a tough federal oversight, the “deferred
prosecution agreement” was accepted by Novelion; the firm paid
$36 million in penalties to the Justice Department and $4.1 million
to the Securities & Exchange Commission. Three former
employees who quit and blew the whistle received $4.7 million as
their share of the government’s recovery.

13. See generally United States v. Aegerion Pharm., Inc., No. 17-10288, 2017
U.S. Dist. LEXIS 191677 (D. Mass. Nov. 20, 2017); see also Press Release, U.S.
Dep’t Justice, Drug Maker Aegerion Agrees to Plead Guilty; Will Pay More Than
$35 Million to Resolve Criminal Charges and Civil False Claims Allegations
(Sept. 22, 2017) (on file with author).
14. See Press Release, U.S. Dep’t Justice, supra note 13.
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I hope we have heard the last; Novelion made no press release,
hopes it will slip quietly through the probationary “deferral”
period, and hopes that it will not be further prosecuted. The drug
remains on the highly specialized cancer market but is not being
offered to doctors “off label” while the tight scrutiny period unfolds.
IV. New Ways of War
That was then, this is now. I speak in past tense terms because
after December 16, 2016, the “off label” promotion moves from
illegal in some doctor’s waiting room to legal in the boardroom of a
health insurance conglomerate. Yes, a new law adopted on that
day will allow the “Formulary Fix,” the targeted promotional
efforts for those as-yet-unapproved medical uses, which now can
legally be promoted.
Promotion of the unapproved use is now permitted to be given
to the set of most influential and powerful drug “payers” like
insurance carriers and state Medicaid agencies, as an expanded
set of benefit claims, for expanding the uses of an already-approved
drug product. Called the 21st Century Cures Act,15 the new
legislation is an important and subtle change to the 1962–2016
way of operating the process for addition of new benefits for
existing licensed drugs. When the new drug approval system was
placed in operation under the 1962 statutory amendments,
healthcare providers did not take their drug decision-making from
large corporate payers like Aetna or Humana or Medicaid; today,
the majority of drug prescribing is being done by employed rather
than independent doctors.16 With employment comes the rules of
the employer; with those rules comes the Formulary Fix. If the cost
to treat this patient is being paid by an entity, it can impose its
restraints on what it will purchase and what its employed
physicians will prescribe. Hence, the patient gets what the
provider sees in the Formulary as the designated drug of choice for
the condition reported by the ailing patient.

15.
16.

Pub. L. No. 114-255, § 3037, 130 Stat. 1033, 1105 (2016).
See generally JAMES O’REILLY & MARY ELLEN KEEGAN, HEALTHCARE
EMPLOYMENT GUIDE (BNA 2017).
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Just as the World War I invention of the armored tank made
horse cavalry obsolete, the Formulary Fix renders the Lanham and
misbranding debates less likely to carry much weight in the future.
The 21st Century Cures Act is subtle but strategic. A drug
development company’s first stage approval of its base line drug
wins approval of the new drug application.17 That company begins
selling that drug for that medical indication. The company soon
realizes its drug could also cure another ailment. At that point, the
company then can choose: it could gather clinical data and ask
FDA to expand the permitted label claims of drug benefit18—the
focus of our drug marketing off-label discussion today. Or, the
company now is able to take the additional medical uses for that
product and present them, not to FDA gatekeepers, but to the
intermediary companies called “pharmacy benefit managers,” the
intermediate players who actually pay for the Medicaid drugs or
who approve the prices that health insurer clients will pay when
they purchase drugs.19
Is the waiting time for FDA’s blessing upon one’s
supplemental new drug application still needed? Times have
changed; in ancient times, Ms. Jones once took a prescription for
acne medication to the Smith Drug Store and paid real cash for the
medication. Today, online promotion to doctors will cut Ms. Jones
out of the decision process; electronic messages from the doctor to
the insurance company will check if the drug that the doctor
wishes to prescribe is “on the (provider’s) Formulary”. If it is, then
the order is passed along electronically to a mail order pharmacy,
and Ms. Jones gets her medicine in one to three days’ delivery.
The Formulary acts as the drug benefit payor’s economic gate
that keeps a $400 headache drug from being prescribed to
customers of XYZ health plan; their Plan makes a
privately-determined cost savings decision to not include a certain
new headache drug in the Formulary. So, the electronic system of
the payer automatically blocks the $400 option for the headache
treatment, while that formulary allows $4 aspirin or $7 Tylenol,
for example. Sitting at the CVS pharmacy waiting for that
prescription to be filled, Ms. Jones has no idea of the hidden role of
17.
18.
19.

21 U.S.C. § 355 (2012).
21 C.F.R. §§ 314.70, 314.80 (2018).
See 21st Century Cures Act § 3037 (amending 21 U.S.C. § 352(a)).
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Pharmacy Benefit Managers. Recall the scene in the “Wizard of
Oz” when the snake oil salesman from Kansas who plays the role
of Oz tells Dorothy: “Pay no attention to that man behind the
curtain!”20 And so decisions today are fast, and denials are less
frequent if the prescriber cooperates.
I realize that this new pharmaceutical sales cycle gets very
complex very quickly, which is why so few members of Congress
understood what they voted for in Section 3037 of the very complex
recent drug legislation. The lobbyists for the drug developers
designed this section to serve as a plausible 2016 alternative to the
decades-old requirement for drug sponsors to be filing clinical
study data with FDA for a “supplemental new drug application.”21
They told Congress it was faster and cheaper to allow the
“Formulary Fix” for these second and subsequent uses of an
already approved drug. Consider a Formulary as an electronic list
of privately reviewed drugs, the prescribing of which is
commercially acceptable to a large health insurer like Humana,
which will accept reimbursement of that drug for certain medical
needs.
The Formulary Fix means that the ability to electronically
order the certain named drugs on the approved-use list will be
available to doctors who work for the entities which take that
insurer’s reimbursement, or whose bills are paid by the company
under a contract. Doctors who use the drugs on that Formulary list
have no problems; but doctors who want to prescribe a different
drug that is not in the formulary have to spend non-compensated
time to justify their preferred drug. I’ll use another model: doctors
treating jaundice can use formulary listed drugs A or B; but if they
want instead to use drug C, that is an exception to the Formulary,
and they will have to spend their own time negotiating with the
corporate staff for an exception which delivers that drug. Yes,
hassling a distant phone contact to get another non-Formulary
drug for a patient is not being reimbursed, so how often will doctors
go “off Formulary” for a call-in support of a different drug for the
needs of one patient? Press “00” if you don’t expect it to happen
often.

20.
21.

L. FRANK BAUM, THE WONDERFUL WIZARD OF OZ (G.M. Co. 1900).
21 C.F.R. §§ 314.70, 314.80.
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So, from 2017 forward, if your company holds the new drug
approval for an acne product, as our hypothetical case had
addressed earlier, your preapproval team no longer need to visit
beautiful White Oak, Maryland to argue with FDA review teams.
Instead, one MBA will head to New York, Nashville, or Boston to
a business office tower where economic choices and medical
decisions are being made. Your technical sales person has power
in 2017 and hereafter, as a result of Section 3037 of the 21st
Century Cures Act, to inform the insurer that your drug cures
hangnail and is cheap and easier to administer.
This is now a normalized stream of product benefit
information. No one needs to stop to ask FDA’s views on clinical
efficacy. The net cost for those patients whose insurer will cover
their drug is less. The sales reps now must try to convince that
company to accept this drug into their “Formulary,” a list matching
illnesses with drugs, a list that is optional and privately compiled,
rather than a federally dictated program. Once you make that
sales pitch successfully, the marketplace of all the patients and
providers of the XYZ insurance group or a state Medicaid program
will be opened to you; and doctors who belong to that health
insurer’s group must begin or continue to use that selected drug
for that “off label” medical indication.
The actual prescriber doctor does not sit in, at the meeting
when the drug maker pitches its drug’s additional use benefit to
the insurer’s formulary committee. Hence, the FDA gatekeeper
roles of the supplemental NDA are inoperative anachronisms,22
and sales will be spurred. Congress ran right past the previous
barrier to adding use information, and “liberated” the drug
marketers for private communication to the few specialist medical
committee members who are the buyers of their mass quantity of
drugs, allowing drug makers to spin the “Formulary Fix”.
V. Trump and Trends
Old, tired veterans of those wars have been alarmed at the
new Trump Administration leadership’s message regarding drug
approvals. Past moments of reflection, like the 100th anniversary
22.

21 CFR §§ 314.70, 314.80.
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symposium of the FDA in 2006, stimulated reflections on the
balance between faster new product approvals, and more certain
decisions in the field of drug safety. The earliest presentations to
industry audiences by the new Commissioner, a longtime industry
advisor and participant, sent a different message and a divergent
tone to the FDA’s review teams. The words of Commissioner Scott
Gottlieb could echo a pharmaceutical industry executive’s
oft-repeated mantra—speed the data gathering and review, speed
the approval, get the drug out today and check the “real world
data” next year.23 It is too early in his leadership term to know
where the acceptance of industry will lead, but there are balanced
approaches that are at some risk of negative consequences in the
Trump Administration’s pro-development rhetoric.
VI. So What?
Battling over the future use of off-label drug claims will be far
less interesting to my hypothetical drug company executive after
2017. She now can gain far more by pressing Humana or Aetna to
place the additional drug benefit claim onto their private
Formulary. If a doctor is in a hospital or practice group whose
Formulary applies controls on what the affiliated physicians can
prescribe, as so many practitioners are and will be, then the
patient record indicates a certain diagnostic code and the patient
gets a prescription for that drug for that non-labeled medical
indication, and the sale is made without need for the old ways of
chasing the off-label violators. The FDA cares less about hangnail;
Jane Insured gets what Doctor Golfclub prescribes; and Golfclub is
directed seamlessly by the drug Formulary, which allows her to
prescribe this drug Alepsima for hangnail.
So, in Shakespeare’s terms, I come to not just praise the Note
by Hurley, but to bury his model of drug marketing. The

23. Scott Gottlieb, M.D., Comm’r of Food & Drugs, Remarks on Leveraging
Quantitative Methods and Modeling to Modernize Generic Drug Development
and Review (Oct. 2, 2017); Scott Gottlieb, M.D., Comm’r of Food and Drugs,
Speech to the 2017 AdvaMed (MedTech) Conference (Sept. 26, 2017); Scott
Gottlieb, M.D., Comm’r of Food and Drugs, Address to National Academy of
Sciences, Advancing Public Health Opportunities with Real World Evidence
(Sept. 19, 2017).
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“Formulary Fix” of Section 3037 of the “21st Century Cures Act”24
is where the marketers of drugs are headed in 2018 and beyond.
The claims of additional benefit that had once languished in FDA’s
in-box are beating a path to Humana’s or McKesson’s door.
While a supplementary new drug application would be nice to
have for the minority of doctors who are not impacted by a
Formulary, the months and millions which such a voluminous
drug application “supplement” demands25 are considerably less
important to net sales goals than they once had been, way back in
2015. The drug promotion effort of this brave new pharma world is
not only centralized and simplified, it is also sanctioned by
Congress as an alternate route to market success.
How this all will play out remains to be seen, and “all the
world’s a stage.”

24. See generally 21st Century Cures Act, Pub. L. No. 114-255, 130 Stat.
1033 (2016).
25. 21 C.F.R. §§ 314.70, 314.80 (2018).

